The clinical and cost-effectiveness of immunoprophylaxis against respiratory syncytial virus with palivizumab in children

Wang D, Cummins C, Bayliss S, Sandercock J, Burls A

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Antibodies, Monoclonal; Antiviral Agents; Child; Cost-Benefit Analysis; Humans; Respiratory Syncytial Virus Infections; Respiratory Tract Infections

AccessionNumber
22008101185

Date bibliographic record published
01/12/2008